CNS Prophylaxis

DRUG2 trials

Sponsors

Gilead Sciences, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, Adult

Phase 1

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

TerminatedNCT02404220

Gilead SciencesAcute Lymphoblastic Leukemia

Start: 2015-05-06End: 2018-12-17Updated: 2020-01-02

Unknown Phase

Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia

Not yet recruitingNCT07495631

Institute of Hematology & Blood Diseases Hospital, ChinaAcute Lymphoblastic Leukemia, Adult

Start: 2026-03-01End: 2030-03-01Target: 80Updated: 2026-03-27

Related Papers

Abstract 819: High response rates with entospletinib in patients with t(v;11q23.3);<i>KMT2A</i> rearranged acute myeloid leukemia and acute lymphoblastic leukemia

Cancer Research2018-07-012 citations

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Blood2015-12-032 citations